Tert-butyl 6-bromo-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-YL)-1H-indole-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Tert-butyl 6-bromo-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-YL)-1H-indole-1-carboxylate
• 英文别名: tert-butyl 6-bromo-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1-carboxylate
• 化学式: C₁₆H₁₃FN₃O₂PolS
• 分子量: 422.1
• InChiKey: LFIDMAGNCYCDBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.49
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Tert-butyl 6-bromo-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-YL)-1H-indole-1-carboxylate 、 异硫氰酸氯代乙酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-(4-(4,5-dihydrothiazol-2-ylamino)phenethyl)-6-fluorobenzo[d]thiazol-2-amine
  参考文献：
  名称：

  [EN] NEUROPEPTIDE RECEPTOR MODULATORS
  [FR] SUBSTANCES MODULATRICES D'UN RECEPTEUR NEUROPEPTIDIQUE

  摘要：

  公开号：

  WO2005111031A3
• 作为产物：
  描述：

  异丙醇频哪醇硼酸酯 在 lithium diisopropyl amide 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 以92%的产率得到Tert-butyl 6-bromo-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-YL)-1H-indole-1-carboxylate
  参考文献：
  名称：

  [EN] PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS
  [FR] DERIVES DE PYRIDAZINONE, PROCEDES DE PRODUCTION DE CES DERIVES ET LEUR UTILISATION COMME PHARMACEUTIQUES

  摘要：

  本发明涉及通式（I）所示的化合物，其中下文给出了取代基X、R1和R2的定义，以及它们的生理上可接受的盐，生产这些化合物的方法以及它们作为药物的用途。通式（I）这些化合物是激酶抑制剂，特别是激酶GSK-15 30（糖原合成酶激酶-3ß）的抑制剂。

  公开号：

  WO2005111018A1

文献信息

• [EN] 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS<br/>[FR] 3-PIPERIDINYLISOCHROMAN-5-OLS UTILISES EN TANT QU'AGONISTES DE LA DOPAMINE
  申请人：AVENTIS PHARMA INC

  公开号：WO2005111025A1

  公开（公告）日：2005-11-24

  The present invention provides compounds of formula (I): a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula (I).

  本发明提供了式(I)的化合物：其立体异构体或药学上可接受的盐，其中变量R1、R2、R3、R4、X和n如此处所定义。另外，提供了一种用于治疗多巴胺相关神经系统疾病的方法，所述疾病包括神经系统、心理、心血管、认知或注意力障碍、物质滥用和成瘾行为，或其组合，包括向需要此类治疗的患者施用式(I)的化合物的治疗有效量。
• PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS
  申请人：Hoelder Swen

  公开号：US20070088041A1

  公开（公告）日：2007-04-19

  The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R 1 and R 2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3β(glycogen synthase kinase-3β).

  本发明涉及符合通式（I）的化合物，其中X，R1和R2的定义如下文所述，以及它们的生理学上可接受的盐，制备这些化合物的方法以及它们作为药物的用途。这些化合物是激酶抑制剂，特别是激酶GSK-3β（糖原合成酶激酶-3β）的抑制剂。
• Pyridazinone derivatives, methods for their production and their use as pharmaceuticals
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US07709466B2

  公开（公告）日：2010-05-04

  The present invention relates to pyridazinone compounds and their derivatives according to the general formula (I), with the substituents X, R1 and R2 defined herein, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3β (glycogen synthase kinase-3β) which are useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome and syndrome X or immunodeficiency.

  本发明涉及吡啶并咪唑酮化合物及其衍生物，其通式（I）中的取代基X，R1和R2的定义，以及其生理上可接受的盐，制备这些化合物的方法以及它们作为药物的用途。这些化合物是激酶抑制剂，特别是激酶GSK-3β（糖原合成酶激酶-3β）的抑制剂，可用于治疗神经退行性疾病，如阿尔茨海默病，帕金森病，中风，头部和脊柱创伤和周围神经病变，肥胖症，代谢性疾病，2型糖尿病，高血压，动脉粥样硬化心血管疾病，多囊卵巢综合症和X综合症或免疫缺陷病。
• Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists
  作者：Zhong-Yue Sun、Zhaoning Zhu、Yuanzan Ye、Brian McKittrick、Michael Czarniecki、William Greenlee、Deborra Mullins、Mario Guzzi

  DOI：10.1016/j.bmcl.2009.09.048

  日期：2009.12

  A class of novel 2-aminobenzothiazoles have been identified as NPY Y-1 antagonists. Various N-heterocyclic substituted aminophenethyl-2-aminobenzothiazole analogs were synthesized to explore the SAR. Isothiourea analogs and ligands with high potency (K-i 30 nM) have been identified. (C) 2009 Elsevier Ltd. All rights reserved.
• [EN] PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DERIVES DE PYRIDAZINONE, PROCEDES DE PRODUCTION DE CES DERIVES ET LEUR UTILISATION COMME PHARMACEUTIQUES
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2005111018A1

  公开（公告）日：2005-11-24

  The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. Formula (I) These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK­15 30 (glycogen synthase kinase-3ß).

  本发明涉及通式（I）所示的化合物，其中下文给出了取代基X、R1和R2的定义，以及它们的生理上可接受的盐，生产这些化合物的方法以及它们作为药物的用途。通式（I）这些化合物是激酶抑制剂，特别是激酶GSK-15 30（糖原合成酶激酶-3ß）的抑制剂。